查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1276883

肝癌症诊断的全球市场:产业趋势与预测(～2030年)

Global Liver Cancer Diagnostics Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 516 Pages | 商品交期: 请询问到货日

价格

全球肝臟癌症诊断的市场规模在2023年～2030年的预测期间将记录6.5％相当的年复合成长率。

全球肝臟癌症盛行率·发病率的上升，肝臟癌症诊断相关认知度提高等，是全球肝臟癌症诊断市场主要成长促进因素。

本报告提供全球肝臟癌症诊断市场相关调查分析，提供市场概要，各市场区隔·各地区的市场分析，竞争分析，企业简介等系统性资讯。

目录

第1章 简介

第2章 市场明细

第3章 摘要整理

第4章 重要考察

  • 大环境分析
  • 波特分析
  • 流行病学

第5章 全球肝臟癌症诊断市场:法规

第6章 产业考察

第7章 市场概要

  • 促进因素
  • 阻碍因素
  • 机会
  • 课题

第8章 全球肝臟癌症诊断市场:检验各类型

  • 概要
  • 影像检查
  • 基因检验
  • 切片检查
  • 其他

第9章 全球肝臟癌症诊断市场:癌症各阶段

  • 概要
  • 阶段III
  • 阶段II
  • 阶段IV
  • 阶段I
  • 阶段0

第10章 全球肝臟癌症诊断市场:癌症各类型

  • 概要
  • 续发性肝臟癌症
  • 原发性肝癌症

第11章 全球肝臟癌症诊断市场:各产品

  • 概要
  • 平台为基础的产品
  • 设备为基础的产品
  • 套件·试剂
  • 其他的消耗品

第12章 全球肝臟癌症诊断市场:各用途

  • 概要
  • 筛检
  • 诊断·预测
  • 预后
  • 研究

第13章 全球肝臟癌症诊断市场:各技术

  • 概要
  • 萤光原位杂合反应
  • 下一代序列
  • 氟免疫化验
  • 比较基因杂合反应
  • 免疫组织化学
  • 其他

第14章 全球肝臟癌症诊断市场:性别

  • 概要
  • 男性
  • 女性

第15章 全球肝臟癌症诊断市场:各终端用户

  • 概要
  • 医院
  • 诊断中心
  • 癌症研究中心
  • 门诊病人手术中心
  • 学术机构
  • 其他

第16章 全球肝臟癌症诊断市场:各流通管道

  • 概要
  • 直接竞标
  • 零售
  • 其他

第17章 全球肝臟癌症诊断市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 俄罗斯
    • 义大利
    • 英国
    • 西班牙
    • 土耳其
    • 荷兰
    • 比利时
    • 瑞士
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 印尼
    • 菲律宾
    • 泰国
    • 澳洲
    • 马来西亚
    • 韩国
    • 新加坡
    • 越南
    • 其他亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他南美
  • 中东·非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 埃及
    • 以色列
    • 其他中东·非洲

第18章 全球肝臟癌症诊断市场:企业形势

  • 企业占有率分析:世界
  • 企业占有率分析:北美
  • 企业占有率分析:欧洲
  • 企业占有率分析:亚太地区

第19章 SWOT分析

第20章 企业简介

  • F. HOFFMANN-LA ROCHE LTD.
  • KONINLIJKE PHILIPS N.V.
  • THERMO FISHER SCIENTIFIC INC.
  • BD
  • SIEMENS HEALTHCARE GMBH
  • AGILENT TECHNOLOGIES, INC.
  • ABK BIOMEDICAL INC.
  • AB SCIEX PTE LTD.(SUBSIDIARY OF DANAHER.)
  • ALTOGEN BIOSYSTEMS
  • BIOCEPT, INC.
  • BODITECH MED INC.
  • DIAGNOSTIC BIOSYSTEMS INC.

The global liver cancer diagnostics market is projected to register a substantial CAGR of 6.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Liver Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I , Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and the rest of Asia-Pacific, South Africa, Saudi Arabia, Egypt, Israel and the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America) - Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global liver cancer diagnostics market are:

Rise in prevalence and incidence of liver cancer in the world

Increase in awareness about the liver cancer diagnostics

Market Players:

Some of the major players operating in the global liver cancer diagnostics market are:

F. Hoffmann-La Roche Ltd.

Koninklijke Philips N.V.

Thermo Fisher Scientific Inc.

BD

Siemens Healthcare GmbH

Agilent Technologies, Inc.

Illumina, Inc.

QIAGEN

FUJIFILM Corporation

Sysmex Corporation AB

Scitex Pte Ltd. (Subsidiary of Danaher.)

Epigenomics AG

Tebubio

Fujirebio

Diagnostic Biosystems Inc.

Q-LINE BIOTECH PVT LTD.

MOLGEN

BIOCEPT, INC.

Boditech Med Inc.

Elabscience Biotechnology Inc.

Hipro Biotechnology Co., Ltd.

Altogen Biosystems

Tosoh India Pvt. Ltd.

ABK Biomedical Inc.

Diazyme Laboratories, Inc.

TABLE OF CONTENTS

1 INTRODUCTION 56

  • 1.1 OBJECTIVES OF THE STUDY 56
  • 1.2 MARKET DEFINITION 56
  • 1.3 OVERVIEW OF THE GLOBAL LIVER CANCER DIAGNOSTICS MARKET 56
  • 1.4 CURRENCY AND PRICING 58
  • 1.5 LIMITATIONS 58
  • 1.6 MARKETS COVERED 59

2 MARKET SEGMENTATION 62

  • 2.1 MARKETS COVERED 62
  • 2.2 GEOGRAPHICAL SCOPE 63
  • 2.3 YEARS CONSIDERED FOR THE STUDY 64
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
  • 2.6 MULTIVARIATE MODELLING 69
  • 2.7 MARKET APPLICATION COVERAGE GRID 70
  • 2.8 TEST TYPE LIFELINE CURVE 71
  • 2.9 DBMR MARKET POSITION GRID 72
  • 2.10 VENDOR SHARE ANALYSIS 73
  • 2.11 SECONDARY SOURCES 74
  • 2.12 ASSUMPTIONS 74

3 EXECUTIVE SUMMARY 75

4 PREMIUM INSIGHTS 78

  • 4.1 PESTLE ANALYSIS 81
  • 4.2 PORTER ANALYSIS 82
  • 4.3 EPIDEMIOLOGY 83

5 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS 84

6 INDUSTRY INSIGHTS 88

7 MARKET OVERVIEW 90

  • 7.1 DRIVERS 92
    • 7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 92
    • 7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER 93
    • 7.1.3 INCREASING CASES OF LIVER CANCER 95
    • 7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS 96
  • 7.2 RESTRAINTS 98
    • 7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS 98
    • 7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS 99
  • 7.3 OPPORTUNITIES 99
    • 7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER 99
    • 7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS 99
    • 7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 100
  • 7.4 CHALLENGES 101
    • 7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS 101
    • 7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 102

8 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 103

  • 8.1 OVERVIEW 104
  • 8.2 IMAGING TEST 107
    • 8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 108
      • 8.2.1.1 MR ANGIOGRAPHY (MRA) 108
      • 8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY 109
    • 8.2.2 COMPUTED TOMOGRAPHY 109
    • 8.2.3 POSITRON EMISSION TOMOGRAPHY 109
    • 8.2.4 ULTRASOUND 109
    • 8.2.5 OTHERS 109
  • 8.3 GENOMIC TEST 109
  • 8.4 BIOPSY 110
    • 8.4.1 FINE NEEDLE ASPIRATION BIOPSY 111
    • 8.4.2 CORE NEEDLE BIOPSY 111
    • 8.4.3 LAPAROSCOPY 111
  • 8.5 OTHERS 112

9 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 113

  • 9.1 OVERVIEW 114
  • 9.2 STAGE III 117
  • 9.3 STAGE II 118
  • 9.4 STAGE IV 119
  • 9.5 STAGE I 120
  • 9.6 STAGE 0 121

10 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 122

  • 10.1 OVERVIEW 123
  • 10.2 SECONDARY LIVER CANCER 126
    • 10.2.1 HEMANGIOMA 127
    • 10.2.2 HEPATIC ADENOMA 127
    • 10.2.3 FOCAL NODULAR HYPERPLASIA 127
  • 10.3 PRIMARY LIVER CANCER 127
    • 10.3.1 HEPATOCELLULAR CARCINOMA (HCC) 128
    • 10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER) 128
    • 10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA 129
    • 10.3.4 HEPATOBLASTOMA 129

11 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT 130

  • 11.1 OVERVIEW 131
  • 11.2 PLATFORM BASED PRODUCTS 134
    • 11.2.1 NEXT GENERATION SEQUENCING 135
    • 11.2.2 MICROARRAYS 135
    • 11.2.3 PCR 135
    • 11.2.4 OTHERS 135
  • 11.3 INSTRUMENT BASED PRODUCTS 135
    • 11.3.1 IMAGING 136
    • 11.3.2 BIOPSY 136
  • 11.4 KITS AND REAGENTS 137
    • 11.4.1 ELISA TEST KITS 138
    • 11.4.2 CASSETTE TEST KITS 138
    • 11.4.3 OTHERS 138
  • 11.5 OTHER CONSUMABLES 138

12 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION 139

  • 12.1 OVERVIEW 140
  • 12.2 SCREENING 143
    • 12.2.1 PLATFORM BASED PRODUCTS 144
    • 12.2.2 INSTRUMENT BASED PRODUCTS 144
    • 12.2.3 KITS AND REAGENTS 144
    • 12.2.4 OTHER CONSUMABLES 144
  • 12.3 DIAGNOSTIC AND PREDICTIVE 144
    • 12.3.1 PLATFORM BASED PRODUCTS 145
    • 12.3.2 INSTRUMENT BASED PRODUCTS 145
    • 12.3.3 KITS AND REAGENTS 145
    • 12.3.4 OTHER CONSUMABLES 146
  • 12.4 PROGNOSTIC 146
    • 12.4.1 PLATFORM BASED PRODUCTS 147
    • 12.4.2 INSTRUMENT BASED PRODUCTS 147
    • 12.4.3 KITS AND REAGENTS 147
    • 12.4.4 OTHER CONSUMABLES 147
  • 12.5 RESEARCH 147
    • 12.5.1 PLATFORM BASED PRODUCTS 149
    • 12.5.2 INSTRUMENT BASED PRODUCTS 149
    • 12.5.3 KITS AND REAGENTS 149
    • 12.5.4 OTHER CONSUMABLES 149

13 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 150

  • 13.1 OVERVIEW 151
  • 13.2 FLUORESCENT IN SITU HYBRIDIZATION 154
  • 13.3 NEXT GENERATION SEQUENCING 155
  • 13.4 FLUORIMMUNOASSAY 156
  • 13.5 COMPARATIVE GENOMIC HYBRIDIZATION 157
  • 13.6 IMMUNOHISTOCHEMICAL 158
  • 13.7 OTHERS 159

14 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY GENDER 160

  • 14.1 OVERVIEW 161
  • 14.2 MALE 164
  • 14.3 FEMALE 165

15 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY END USER 166

  • 15.1 OVERVIEW 167
  • 15.2 HOSPITALS 170
  • 15.3 DIAGNOSTIC CENTERS 171
  • 15.4 CANCER RESEARCH CENTERS 172
  • 15.5 AMBULATORY SURGICAL CENTERS 173
  • 15.6 ACADEMIC INSTITUTES 174
  • 15.7 OTHERS 175

16 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 176

  • 16.1 OVERVIEW 177
  • 16.2 DIRECT TENDER 180
  • 16.3 RETAIL SALES 181
  • 16.4 OTHERS 182

17 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY REGION 183

  • 17.1 OVERVIEW 184
  • 17.2 NORTH AMERICA 190
    • 17.2.1 U.S. 203
    • 17.2.2 CANADA 211
    • 17.2.3 MEXICO 219
  • 17.3 EUROPE 227
    • 17.3.1 GERMANY 240
    • 17.3.2 FRANCE 248
    • 17.3.3 RUSSIA 256
    • 17.3.4 ITALY 263
    • 17.3.5 U.K. 271
    • 17.3.6 SPAIN 278
    • 17.3.7 TURKEY 285
    • 17.3.8 NETHERLANDS 292
    • 17.3.9 BELGIUM 300
    • 17.3.10 SWITZERLAND 308
    • 17.3.11 REST OF EUROPE 316
  • 17.4 ASIA-PACIFIC 317
    • 17.4.1 CHINA 328
    • 17.4.2 INDIA 334
    • 17.4.3 JAPAN 340
    • 17.4.4 INDONESIA 346
    • 17.4.5 PHILIPPINES 352
    • 17.4.6 THAILAND 358
    • 17.4.7 AUSTRALIA 364
    • 17.4.8 MALAYSIA 370
    • 17.4.9 SOUTH KOREA 376
    • 17.4.10 SINGAPORE 382
    • 17.4.11 VIETNAM 388
    • 17.4.12 REST OF ASIA-PACIFIC 394
  • 17.5 SOUTH AMERICA 395
    • 17.5.1 BRAZIL 408
    • 17.5.2 ARGENTINA 416
    • 17.5.3 REST OF SOUTH AMERICA 424
  • 17.6 MIDDLE EAST AND AFRICA 425
    • 17.6.1 SOUTH AFRICA 436
    • 17.6.2 SAUDI ARABIA 442
    • 17.6.3 U.A.E. 448
    • 17.6.4 EGYPT 454
    • 17.6.5 ISRAEL 460
    • 17.6.6 REST OF MIDDLE EAST AND AFRICA 466

18 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 467

  • 18.1 COMPANY SHARE ANALYSIS: GLOBAL 467
  • 18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 468
  • 18.3 COMPANY SHARE ANALYSIS: EUROPE 469
  • 18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 470

19 SWOT ANALYSIS 471

20 COMPANY PROFILE 472

  • 20.1 F. HOFFMANN-LA ROCHE LTD. 472
    • 20.1.1 COMPANY SNAPSHOT 472
    • 20.1.2 REVENUE ANALYSIS 472
    • 20.1.3 COMPANY SHARE ANALYSIS 473
    • 20.1.4 PRODUCT PORTFOLIO 473
    • 20.1.5 RECENT DEVELOPMENT 473
  • 20.2 KONINLIJKE PHILIPS N.V. 474
    • 20.2.1 COMPANY SNAPSHOT 474
    • 20.2.2 REVENUE ANALYSIS 474
    • 20.2.3 COMPANY SHARE ANALYSIS 475
    • 20.2.4 PRODUCT PORTFOLIO 475
    • 20.2.5 RECENT DEVELOPMENT 475
  • 20.3 THERMO FISHER SCIENTIFIC INC. 476
    • 20.3.1 COMPANY SNAPSHOT 476
    • 20.3.2 REVENUE ANALYSIS 476
    • 20.3.3 COMPANY SHARE ANALYSIS 477
    • 20.3.4 PRODUCT PORTFOLIO 477
    • 20.3.5 RECENT DEVELOPMENT 477
  • 20.4 BD 478
    • 20.4.1 COMPANY SNAPSHOT 478
    • 20.4.2 REVENUE ANALYSIS 478
    • 20.4.3 COMPANY SHARE ANALYSIS 479
    • 20.4.4 PRODUCT PORTFOLIO 479
    • 20.4.5 RECENT DEVELOPMENTS 480
  • 20.5 SIEMENS HEALTHCARE GMBH 481
    • 20.5.1 COMPANY SNAPSHOT 481
    • 20.5.2 REVENUE ANALYSIS 481
    • 20.5.3 COMPANY SHARE ANALYSIS 482
    • 20.5.4 PRODUCT PORTFOLIO 482
    • 20.5.5 RECENT DEVELOPMENT 482
  • 20.6 AGILENT TECHNOLOGIES, INC. 483
    • 20.6.1 COMPANY SNAPSHOT 483
    • 20.6.2 REVENUE ANALYSIS 483
    • 20.6.3 PRODUCT PORTFOLIO 484
    • 20.6.4 RECENT DEVELOPMENTS 484
  • 20.7 ABK BIOMEDICAL INC. 485
    • 20.7.1 COMPANY SNAPSHOT 485
    • 20.7.2 PRODUCT PORTFOLIO 485
    • 20.7.3 RECENT DEVELOPMENT 485
  • 20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.) 486
    • 20.8.1 COMPANY SNAPSHOT 486
    • 20.8.2 REVENUE ANALYSIS 486
    • 20.8.3 PRODUCT PORTFOLIO 487
    • 20.8.4 RECENT DEVELOPMENT 487
  • 20.9 ALTOGEN BIOSYSTEMS 488
    • 20.9.1 COMPANY SNAPSHOT 488
    • 20.9.2 PRODUCT PORTFOLIO 488
    • 20.9.3 RECENT DEVELOPMENT 488
  • 20.10 BIOCEPT, INC. 489
    • 20.10.1 COMPANY SNAPSHOT 489
    • 20.10.2 REVENUE ANALYSIS 489
    • 20.10.3 PRODUCT PORTFOLIO 490
    • 20.10.4 RECENT DEVELOPMENT 490
  • 20.11 BODITECH MED INC. 491
    • 20.11.1 COMPANY SNAPSHOT 491
    • 20.11.2 PRODUCT PORTFOLIO 491
    • 20.11.3 RECENT DEVELOPMENTS 491
  • 20.12 DIAGNOSTIC BIOSYSTEMS INC. 492
    • 20.12.1 COMPANY SNAPSHOT 492
    • 20.12.2 PRODUCT PORTFOLIO 492
    • 20.12.3 RECENT DEVELOPMENT 492
  • 20.13 DIAZYME LABORATORIES, INC. 493
    • 20.13.1 COMPANY SNAPSHOT 493
    • 20.13.2 PRODUCT PORTFOLIO 493
    • 20.13.3 RECENT DEVELOPMENT 493
  • 20.14 ELABSCIENCE BIOTECHNOLOGY INC. 494
    • 20.14.1 COMPANY SNAPSHOT 494
    • 20.14.2 PRODUCT PORTFOLIO 494
    • 20.14.3 RECENT DEVELOPMENT 494
  • 20.15 EPIGENOMICS AG 495
    • 20.15.1 COMPANY SNAPSHOT 495
    • 20.15.2 REVENUE ANALYSIS 495
    • 20.15.3 PRODUCT PORTFOLIO 496
    • 20.15.4 RECENT DEVELOPMENT 496
  • 20.16 FUJIFILM CORPORATION 497
    • 20.16.1 COMPANY SNAPSHOT 497
    • 20.16.2 REVENUE ANALYSIS 497
    • 20.16.3 PRODUCT PORTFOLIO 498
    • 20.16.4 RECENT DEVELOPMENT 498
  • 20.17 FUJIREBIO 499
    • 20.17.1 COMPANY SNAPSHOT 499
    • 20.17.2 PRODUCT PORTFOLIO 499
    • 20.17.3 RECENT DEVELOPMENTS 499
  • 20.18 HIPRO BIOTECHNOLOGY CO., LTD. 500
    • 20.18.1 COMPANY SNAPSHOT 500
    • 20.18.2 PRODUCT PORTFOLIO 500
    • 20.18.3 RECENT DEVELOPMENT 500
  • 20.19 ILLUMINA, INC. 501
    • 20.19.1 COMPANY SNAPSHOT 501
    • 20.19.2 REVENUE ANALYSIS 501
    • 20.19.3 PRODUCT PORTFOLIO 502
    • 20.19.4 RECENT DEVELOPMENTS 503
  • 20.20 MOLGEN 504
    • 20.20.1 COMPANY SNAPSHOT 504
    • 20.20.2 PRODUCT PORTFOLIO 504
    • 20.20.3 RECENT DEVELOPMENT 504
  • 20.21 QIAGEN 505
    • 20.21.1 COMPANY SNAPSHOT 505
    • 20.21.2 REVENUE ANALYSIS 505
    • 20.21.3 PRODUCT PORTFOLIO 506
    • 20.21.4 RECENT DEVELOPMENT 506
  • 20.22 Q-LINE BIOTECH PVT LTD. 507
    • 20.22.1 COMPANY SNAPSHOT 507
    • 20.22.2 PRODUCT PORTFOLIO 507
    • 20.22.3 RECENT DEVELOPMENT 507
  • 20.23 SYSMEX CORPORATION 508
    • 20.23.1 COMPANY SNAPSHOT 508
    • 20.23.2 REVENUE ANALYSIS 508
    • 20.23.3 PRODUCT PORTFOLIO 509
    • 20.23.4 RECENT DEVELOPMENT 509
  • 20.24 TEBUBIO 510
    • 20.24.1 COMPANY SNAPSHOT 510
    • 20.24.2 PRODUCT PORTFOLIO 510
    • 20.24.3 RECENT DEVELOPMENT 510
  • 20.25 TOSOH INDIA PVT. LTD. 511
    • 20.25.1 COMPANY SNAPSHOT 511
    • 20.25.2 PRODUCT PORTFOLIO 511
    • 20.25.3 RECENT DEVELOPMENT 511

21 QUESTIONNAIRE 512

22 RELATED REPORTS 516

LIST OF TABLES

  • TABLE 1 DIFFERENT TYPES OF CANCER NON-INVASIVE SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS 93
  • TABLE 2 LIVER CANCER RATES 96
  • TABLE 3 APPROVED DIAGNOSTICS OF LIVER CANCER 97
  • TABLE 4 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 5 GLOBAL IMAGING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
  • TABLE 6 GLOBAL IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 7 GLOBAL MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 8 GLOBAL GENETIC TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
  • TABLE 9 GLOBAL BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
  • TABLE 10 GLOBAL BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 11 GLOBAL OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
  • TABLE 12 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 116
  • TABLE 13 GLOBAL STAGE III IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 117
  • TABLE 14 GLOBAL STAGE II IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
  • TABLE 15 GLOBAL STAGE IV IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
  • TABLE 16 GLOBAL STAGE I IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
  • TABLE 17 GLOBAL STAGE 0 IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
  • TABLE 18 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 19 GLOBAL SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
  • TABLE 20 GLOBAL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 21 GLOBAL CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
  • TABLE 22 GLOBAL CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 23 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 133
  • TABLE 24 GLOBAL PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 134
  • TABLE 25 GLOBAL PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 134
  • TABLE 26 GLOBAL INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 27 GLOBAL INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 136
  • TABLE 28 GLOBAL KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
  • TABLE 29 GLOBAL KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 137
  • TABLE 30 GLOBAL OTHER CONSUMABLES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
  • TABLE 31 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 142
  • TABLE 32 GLOBAL SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 143
  • TABLE 33 GLOBAL SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 143
  • TABLE 34 GLOBAL DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
  • TABLE 35 GLOBAL DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 145
  • TABLE 36 GLOBAL PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 37 GLOBAL PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 147
  • TABLE 38 GLOBAL RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 148
  • TABLE 39 GLOBAL RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 148
  • TABLE 40 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 153
  • TABLE 41 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
  • TABLE 42 GLOBAL NEXT GENERATION SEQUENCING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 155
  • TABLE 43 GLOBAL FLUORIMMUNOASSAY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 156
  • TABLE 44 GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 157
  • TABLE 45 GLOBAL IMMUNOHISTOCHEMICAL IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 158
  • TABLE 46 GLOBAL OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 159
  • TABLE 47 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 163
  • TABLE 48 GLOBAL MALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 164
  • TABLE 49 GLOBAL FEMALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 165
  • TABLE 50 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 169
  • TABLE 51 GLOBAL HOSPITALS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 170
  • TABLE 52 GLOBAL DIAGNOSTIC CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 171
  • TABLE 53 GLOBAL CANCER RESEARCH CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 172
  • TABLE 54 GLOBAL AMBULATORY SURGICAL CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 173
  • TABLE 55 GLOBAL ACADEMIC INSTITUTES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 174
  • TABLE 56 GLOBAL OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 175
  • TABLE 57 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 179
  • TABLE 58 GLOBAL DIRECT TENDER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 180
  • TABLE 59 GLOBAL RETAIL SALES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 181
  • TABLE 60 GLOBAL OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 182
  • TABLE 61 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 189
  • TABLE 62 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 195
  • TABLE 63 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 64 NORTH AMERICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 65 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 196
  • TABLE 66 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 67 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 197
  • TABLE 68 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 69 NORTH AMERICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 70 NORTH AMERICA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 198
  • TABLE 71 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 198
  • TABLE 72 NORTH AMERICA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 198
  • TABLE 73 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 199
  • TABLE 74 NORTH AMERICA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 199
  • TABLE 75 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 199
  • TABLE 76 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 200
  • TABLE 77 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 200
  • TABLE 78 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 200
  • TABLE 79 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 201
  • TABLE 80 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 201
  • TABLE 81 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 201
  • TABLE 82 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 202
  • TABLE 83 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 202
  • TABLE 84 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 203
  • TABLE 85 U.S. IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 203
  • TABLE 86 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 204
  • TABLE 87 U.S. BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 204
  • TABLE 88 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 204
  • TABLE 89 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 205
  • TABLE 90 U.S. SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 205
  • TABLE 91 U.S. PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 205
  • TABLE 92 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 206
  • TABLE 93 U.S. PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 206
  • TABLE 94 U.S. INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 206
  • TABLE 95 U.S. KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 207
  • TABLE 96 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 207
  • TABLE 97 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 207
  • TABLE 98 U.S. SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 208
  • TABLE 99 U.S. DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 208
  • TABLE 100 U.S. PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 208
  • TABLE 101 U.S. RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 209
  • TABLE 102 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 209
  • TABLE 103 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 209
  • TABLE 104 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 210
  • TABLE 105 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 211
  • TABLE 106 CANADA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 211
  • TABLE 107 CANADA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 211
  • TABLE 108 CANADA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 212
  • TABLE 109 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 212
  • TABLE 110 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 212
  • TABLE 111 CANADA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 213
  • TABLE 112 CANADA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 213
  • TABLE 113 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 213
  • TABLE 114 CANADA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 214
  • TABLE 115 CANADA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 214
  • TABLE 116 CANADA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 214
  • TABLE 117 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 215
  • TABLE 118 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 215
  • TABLE 119 CANADA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 216
  • TABLE 120 CANADA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 216
  • TABLE 121 CANADA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 216
  • TABLE 122 CANADA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 217
  • TABLE 123 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 217
  • TABLE 124 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 217
  • TABLE 125 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 218
  • TABLE 126 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 219
  • TABLE 127 MEXICO IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 219
  • TABLE 128 MEXICO MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 220
  • TABLE 129 MEXICO BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 220
  • TABLE 130 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 220
  • TABLE 131 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 221
  • TABLE 132 MEXICO SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 221
  • TABLE 133 MEXICO PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 221
  • TABLE 134 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 222
  • TABLE 135 MEXICO PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 222
  • TABLE 136 MEXICO INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 222
  • TABLE 137 MEXICO KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 223
  • TABLE 138 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 223
  • TABLE 139 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 223
  • TABLE 140 MEXICO SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 224
  • TABLE 141 MEXICO DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 224
  • TABLE 142 MEXICO PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 224
  • TABLE 143 MEXICO RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 225
  • TABLE 144 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 225
  • TABLE 145 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 225
  • TABLE 146 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 226
  • TABLE 147 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 232
  • TABLE 148 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 149 EUROPE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 233
  • TABLE 150 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 233
  • TABLE 151 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 233
  • TABLE 152 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 234
  • TABLE 153 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 234
  • TABLE 154 EUROPE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 234
  • TABLE 155 EUROPE PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 235
  • TABLE 156 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 235
  • TABLE 157 EUROPE PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 235
  • TABLE 158 EUROPE INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 236
  • TABLE 159 EUROPE KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 236
  • TABLE 160 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 236
  • TABLE 161 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 237
  • TABLE 162 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 237
  • TABLE 163 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 237
  • TABLE 164 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 238
  • TABLE 165 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 238
  • TABLE 166 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 238
  • TABLE 167 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 239
  • TABLE 168 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 239
  • TABLE 169 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 170 GERMANY IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 171 GERMANY MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 240
  • TABLE 172 GERMANY BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 173 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 241
  • TABLE 174 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 175 GERMANY SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 176 GERMANY PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 177 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 242
  • TABLE 178 GERMANY PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 243
  • TABLE 179 GERMANY INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 243
  • TABLE 180 GERMANY KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 243
  • TABLE 181 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 244
  • TABLE 182 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 244
  • TABLE 183 GERMANY SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 245
  • TABLE 184 GERMANY DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 245
  • TABLE 185 GERMANY PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 245
  • TABLE 186 GERMANY RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 246
  • TABLE 187 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 246
  • TABLE 188 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 246
  • TABLE 189 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 247
  • TABLE 190 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 248
  • TABLE 191 FRANCE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 248

LIST OF FIGURES

  • FIGURE 1 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION 62
  • FIGURE 2 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 65
  • FIGURE 3 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 66
  • FIGURE 4 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 67
  • FIGURE 5 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 67
  • FIGURE 6 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 68
  • FIGURE 7 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 70
  • FIGURE 8 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 72
  • FIGURE 9 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 73
  • FIGURE 10 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION 77
  • FIGURE 11 GROWING AWARENESS OF LIVER CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL LIVER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 78
  • FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LIVER CANCER DIAGNOSTICS MARKET IN 2023 & 2030 78
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL LIVER CANCER DIAGNOSTICS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 79
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR LIVER CANCER DIAGNOSTIC MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 80
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL LIVER CANCER DIAGNOSTICS MARKET 91
  • FIGURE 16 THE GLOBAL MORTALITY RATE DUE TO CANCER 94
  • FIGURE 17 INCREASING GLOBAL CANCER RATE IN 2020 95
  • FIGURE 18 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT 98
  • FIGURE 19 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 104
  • FIGURE 20 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 105
  • FIGURE 21 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 105
  • FIGURE 22 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 106
  • FIGURE 23 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2022 114
  • FIGURE 24 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION) 115
  • FIGURE 25 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030) 115
  • FIGURE 26 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE 116
  • FIGURE 27 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 123
  • FIGURE 28 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 124
  • FIGURE 29 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 124
  • FIGURE 30 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 125
  • FIGURE 31 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022 131
  • FIGURE 32 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 132
  • FIGURE 33 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030) 132
  • FIGURE 34 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE 133
  • FIGURE 35 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022 140
  • FIGURE 36 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 141
  • FIGURE 37 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030) 141
  • FIGURE 38 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE 142
  • FIGURE 39 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022 151
  • FIGURE 40 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 152
  • FIGURE 41 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030) 152
  • FIGURE 42 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE 153
  • FIGURE 43 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2022 161
  • FIGURE 44 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 162
  • FIGURE 45 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 162
  • FIGURE 46 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 163
  • FIGURE 47 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2022 167
  • FIGURE 48 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 168
  • FIGURE 49 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 168
  • FIGURE 50 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 169
  • FIGURE 51 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 177
  • FIGURE 52 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 178
  • FIGURE 53 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 178
  • FIGURE 54 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 179
  • FIGURE 55 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 185
  • FIGURE 56 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY REGION (2022) 187
  • FIGURE 57 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 187
  • FIGURE 58 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 188
  • FIGURE 59 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030) 188
  • FIGURE 60 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 191
  • FIGURE 61 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 193
  • FIGURE 62 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 193
  • FIGURE 63 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 194
  • FIGURE 64 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 194
  • FIGURE 65 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 228
  • FIGURE 66 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 230
  • FIGURE 67 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 230
  • FIGURE 68 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 231
  • FIGURE 69 EUROPE LIVER CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 231
  • FIGURE 70 ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 318
  • FIGURE 71 ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 320
  • FIGURE 72 ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 320
  • FIGURE 73 ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 321
  • FIGURE 74 ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 321
  • FIGURE 75 SOUTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 396
  • FIGURE 76 SOUTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 398
  • FIGURE 77 SOUTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 398
  • FIGURE 78 SOUTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 399
  • FIGURE 79 SOUTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 399
  • FIGURE 80 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 426
  • FIGURE 81 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 428
  • FIGURE 82 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 428
  • FIGURE 83 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 429
  • FIGURE 84 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 429
  • FIGURE 85 GLOBAL LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 467
  • FIGURE 86 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 468
  • FIGURE 87 EUROPE LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 469
  • FIGURE 88 ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 470